Health · Pharma & Biotech · 20 hrs ago
Early APN401 studies report safety and disease stabilization in some patients
A peer-reviewed journal has published findings from two Phase 1 studies of APN401, an experimental cell therapy made from patients’ own immune cells.
The studies involved 17 people with advanced solid tumors that had not responded to earlier treatment; they had received between two and 11 prior treatment lines.
The treatment was well tolerated, with no dose-limiting toxicities or other listed severe treatment-related effects.
Among 10 patients whose disease could be assessed using standard criteria, five had stable disease, meaning their cancer did not show clear growth or shrinkage during assessment.
Researchers also found changes in immune activity after treatment, especially among patients with stable disease, but the results do not establish that APN401 caused this outcome.
Further clinical evaluation is needed, and the company says the findings support continuing study of the treatment and its manufacturing process.
A peer-reviewed report describes two Phase 1 studies of APN401 in patients with advanced, treatment-refractory solid tumors.
All 17 patients who received the therapy across three dose levels tolerated it without dose-limiting toxicities or severe treatment-related adverse events.
Disease stabilization was observed in 5 of 10 patients whose disease could be evaluated under RECIST criteria.
The highest tested dose, 4.5 × 10^7 PBMCs per kilogram, was selected as the recommended Phase 2 dose.
The findings included immune changes that were most pronounced in patients with stable disease, and the company said further clinical evaluation is supported.
- Who
- Seventeen patients with advanced, treatment-refractory solid tumors received APN401.
- What
- Two Phase 1 studies evaluated the safety and clinical findings of the autologous cell therapy.
- When
- The data were announced on October 16, 2026.
- Where
- The findings were published in Molecular Therapy Oncology. Study locations are not stated.
- Why
- The studies evaluated APN401 as a potential treatment for advanced solid tumors.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Patients treated
- 17 across three dose levels
- Prior treatment
- Two to eleven lines of systemic therapy
- Disease stabilization
- 5 of 10 RECIST-evaluable patients
- Recommended Phase 2 dose
- 4.5 × 10^7 PBMCs/kg
- Severe treatment-related adverse events
- None at grade 3 or higher
What people are saying
We are encouraged by the favorable safety profile, the disease stabilization observed, and the systemic immune changes following treatment.